Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease

Citations Over TimeTop 1% of 2012 papers

Abstract

We report the results of a long-term follow-up of subjects in a phase 1 study of AAV2-hAADC (adeno-associated virus type 2-human aromatic L-amino acid decarboxylase) gene therapy for the treatment of Parkinson's disease (PD). Ten patients with moderately advanced PD received bilateral putaminal infusions of either a low or a high dose of AAV2-hAADC vector. An annual positron emission tomography (PET) imaging with [(18)F]fluoro-L-m-tyrosine tracer was used for evaluation of AADC expression, and a standard clinical rating scale [Unified Parkinson's Disease Rating Scale (UPDRS)] was used to assess effect. Our previous analysis of the 6-month data suggested that this treatment was acutely safe and well tolerated. We found that the elevated PET signal observed in the first 12 months persisted over 4 years in both dose groups. A significantly increased PET value compared with the presurgery baseline was maintained over the 4-year monitoring period. The UPDRS in all patients off medication for 12 hr improved in the first 12 months, but displayed a slow deterioration in subsequent years. This analysis demonstrates that apparent efficacy continues through later years with an acceptable safety profile. These data indicate stable transgene expression over 4 years after vector delivery and continued safety, but emphasize the need for a controlled efficacy trial and the use of a higher vector dose.

Related Papers

• → Usefulness of Parkinson's KinetiGraph in a Parkinson's disease clinic – Survey of 82 patients(2015)3 cited
• → Short-Term Service in Fiji Yields Long-Term Benefits(2008)1 cited
• → Imagination and education in Australia: Short term fixes or long-term gains?(2012)1 cited
• → House Passes Short-Term SGR Fix, But Long-Term Solution Still MIA(2010)
• → Inferring the Long-Term Causal Effects of Long-Term Treatments from Short-Term Experiments(2023)